Exclusive Interview: Dean Petkanas, CEO, KannaLife
(The Company Just Awarded An Exclusive Cannabinoid License By The Federal Government)
The exclusive rights to apply the cannabinoids found in marijuana as therapeutic agents awarded by the U.S. federal government to the firm KannaLife only apply to one specific medical condition, KannaLife’s CEO told Toke of the Town Monday night.
Dean Petkanas, chief executive officer at
KannaLife Sciences, told us that the exclusivity applies only for the development and sale of cannabinoid based therapeutics as antioxidants and neuroprotectants for use in the treatment of
hepatic encephalopathy.
“It is narrowly defined exclusivity, in that field,” Petkanas told us. “Our exclusivity is narrowly focused.”
Asked if KannaLife planned to get exclusive rights to develop cannabinoids to treat other conditions, Petkanas answered, “At the present time, we have no desire to do that.”